PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability
Brunnström H, Johansson A, Westbom-Fremer S, Backman M, Djureinovic D, Patthey A, Isaksson-Mettävainio M, Gulyas M, Micke P. PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. Modern Pathology 2017, 30: 1411-1421. PMID: 28664936, DOI: 10.1038/modpathol.2017.59.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsB7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungHumansImmunohistochemistryLung NeoplasmsMolecular Targeted TherapyObserver VariationPathologistsConceptsPositive tumor cellsTumor cellsLung cancerPD-L1 checkpoint inhibitorsPD-L1 assaysPD-L1 immunohistochemistryCell death 1Squamous cell carcinomaPD-L1 scoresLung cancer casesCheckpoint inhibitorsDeath-1Cell carcinomaClinical studiesCancer casesImmunohistochemical stainingTissue microarrayInterrater variationAntibody 22C3Cutoff levelInter-pathologist variabilityTumor tissueClinical settingSP142Antibody clones